【product description】

Tofacitinib is a JAK inhibitor that reduces cytokine signaling, cytokine-induced gene expression and cell activation by inhibiting the JAK pathway, thereby reducing a variety of chronic inflammatory responses.

In March 2017, the China Food and Drug Administration approved tofacitinib for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have insufficient efficacy or tolerance to methotrexate, and can be combined with methotrexate Or other DMARD drugs used in combination, the trade name is “Shangjie”.

Up to now, tofacitinib has been approved for use in more than 50 countries around the world, and has been recommended as the drug of choice by several international rheumatoid arthritis treatment guidelines, including European League Against Rheumatism (EULAR), American College of Rheumatology, etc. (ACR) and the Alliance of Asia Pacific Societies of Rheumatology (APLAR).

In December 2017, the US FDA approved tofacitinib for the treatment of adult patients with active psoriatic arthritis (Psoriatic Arthritis, PsA), these patients respond to methotrexate (methotrexate) or other disease-modifying antirheumatic drugs Inadequate ate response or tolerance to DMARDs.

In March 2018, the US FDA approved tofacitinib for the treatment of moderately to severely active ulcerative colitis (UC). Ulcerative colitis is a chronic, debilitating, often misunderstood inflammatory bowel disease that affects millions of people worldwide with sys mptoms including chronic diarrhea with blood and mucus, abdominal pain, cramps, fever, weight loss, and more.

In addition, numerous clinical data show that tofacitinib has good curative effect in the treatment of various autoimmune diseases such as ankylosing spondylitis, alopecia areata (baldness with immune system disorders), vitiligo treatment and systemic lupus erythematosus .

【Indications】

1. For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have poor response to or cannot tolerate methotrexate, and can be used as monotherapy or combined with methotrexate or other non-biological product disease- modifying anti-inflammatory Drugs Combination of rheumatic drugs (DMARDs);
2. For the treatment of active psoriatic arthritis (PsA);
3. For the treatment of moderately to severely active ulcerative colitis (UC)

【Dosage】

The recommended dose of Tofacitinib tablets is 5 mg, orally, 2 times a day, 5 mg each time.
Take with or without food, do not crush, split or chew tablets